Patents by Inventor Kenneth Alan Jacobson

Kenneth Alan Jacobson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment and prevention of neuropathic pain with P2Y14 antagonists
    Patent number: 11708346
    Abstract: Disclosed herein are methods for treating neuropathic pain in a subject in need thereof. The methods include: administering to a subject in need thereof a therapeutically effective amount of an antagonist of P2Y14.
    Type: Grant
    Filed: July 23, 2020
    Date of Patent: July 25, 2023
    Assignee: Saint Louis University
    Inventors: Daniela Salvemini, Kenneth Alan Jacobson
  • TREATMENT AND PREVENTION OF NEUROPATHIC PAIN WITH P2Y14 ANTAGONISTS
    Publication number: 20210024489
    Abstract: Disclosed herein are methods for treating neuropathic pain in a subject in need thereof. The methods include: administering to a subject in need thereof a therapeutically effective amount of an antagonist of P2Y14.
    Type: Application
    Filed: July 23, 2020
    Publication date: January 28, 2021
    Inventors: Daniela Salvemini, Kenneth Alan Jacobson
  • METHANOCARBA DERIVATIVES OF PSEUDORIBOSE THAT INHIBIT ADENOSINE KINASE
    Publication number: 20190038627
    Abstract: Adenosine kinase inhibitors, including pharmaceutical compositions containing the adenosine kinase inhibitors, and their use for preventing epilepsy and its progression in patients. The adenosine kinase inhibitors have the formula: where the moieties J and K, considered in combination, are —CH2—, or K and L, considered in combination, are —CH2—. The R1 moiety can be —NH2, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 hydroxyalkyl. The R2 and R3 moieties are each independently C1-C6 alkyl. The R4 moiety is hydrogen or C1-C6 alkyl. The R5 and R6 moieties are each independently C6-C12 aryl, C3-C8 cycloalkyl, or C3-C8 heteroaryl, that is optionally further substituted.
    Type: Application
    Filed: July 9, 2018
    Publication date: February 7, 2019
    Applicants: Legacy Emanuel Hospital & Health Center, The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Kenneth Alan Jacobson, Detlev Boison, Kiran Shambhu Toti
  • Methanocarba derivatives of pseudoribose that inhibit adenosine kinase
    Patent number: 10016432
    Abstract: Adenosine kinase inhibitors, including pharmaceutical compositions containing the adenosine kinase inhibitors, and their use for preventing epilepsy and its progression in patients. The adenosine kinase inhibitors have the formula: where the moieties J and K, considered in combination, are —CH2—, or K and L, considered in combination, are —CH2—. The R1 moiety can be —NH2, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 hydroxyalkyl. The R2 and R3 moieties are each independently C1-C6 alkyl. The R4 moiety is hydrogen or C1-C6 alkyl. The R5 and R6 moieties are each independently C6-C12 aryl, C3-C8 cycloalkyl, or C3-C8 heteroaryl, that is optionally further substituted.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: July 10, 2018
    Assignees: Legacy Emanuel Hospital & Health Center, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Kenneth Alan Jacobson, Detlev Boison, Kiran Shambhu Toti
  • METHANOCARBA DERIVATIVES OF PSEUDORIBOSE THAT INHIBIT ADENOSINE KINASE
    Publication number: 20170340640
    Abstract: Adenosine kinase inhibitors, including pharmaceutical compositions containing the adenosine kinase inhibitors, and their use for preventing epilepsy and its progression in patients. The adenosine kinase inhibitors have the formula: where the moieties J and K, considered in combination, are —CH2—, or K and L, considered in combination, are —CH2—. The R1 moiety can be —NH2, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 hydroxyalkyl. The R2 and R3 moieties are each independently C1-C6 alkyl. The R4 moiety is hydrogen or C1-C6 alkyl. The R5 and R6 moieties are each independently C6-C12 aryl, C3-C8 cycloalkyl, or C3-C8 heteroaryl, that is optionally further substituted.
    Type: Application
    Filed: May 26, 2017
    Publication date: November 30, 2017
    Applicants: Legacy Emanuel Hospital & Health Center, The United States of America, as represented by The Secretary, Department of Health and Human Serv
    Inventors: Kenneth Alan Jacobson, Detlev Boison, Kiran Shambhu Toti